Allergy Care Market Size to Expand at the CAGR of 4.0% During 2018 to 2027

The allergy care market is expected to remain consolidated among Tier 1 players, who currently account for approximately 75% share. While these players are focusing on expansion in manufacturing facilities and strategic alliances with regional distributors, small and mid-sized players are eyeing partnerships with local players and strengthening their regional presence.

Request to View Sample of Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=2382

Allergy care medication sales will remain consolidated in drug & pharmacies stores, accounting for over 50% share in 2018. Availability of a wide variety of kits in drug stores, devoid of the need for prescription has further led affected individuals to buy medicines respective to their ailments from these stores. However, online retailers are fast gaining palpability in the allergy care market, enabling consumers to purchase their medication with the comfort of their home and at relatively affordable costs.

Revenues from Antihistamine Medication to be 1.5X of Nasal Spray

Antihistamine medication has traditionally been in high demand, with over US$ 2000 Mn worth sales estimated in 2018. Revenues from antihistamine medication is expected to be nearly 1.5X than those from nasal spray sales worldwide in 2018. Antihistamines have emerged as an effective medication to manage allergies such as urticarial, conjunctivitis, and rhinitis. Newer antihistamines introduced in the market are less sedative their traditional counterparts, and are deemed efficacious through head-to-head long-term studies.

GPs from leading healthcare institutes have been working on the assessment of allergy management support system’s (AMSS) feasibility for IgE-mediated allergy care. Effective development of an AMSS would further aid GPs in handling the increasing burden of managing allergic diseases, as well as facilitate diagnosis and treatment of various allergy-affected individuals. However, further research is essential for rolling out the technology on a full scale.

Allergy care market remains highly consolidated, with leading players holding around 70-75 revenue share. The focal point of these leading players in the allergy care market is expansion of manufacturing facilities to rev up their production capabilities. Moreover, these companies are also focusing on strategic collaborations with healthcare professionals to excel in multiple activities, ranging from preclinical research to clinical development.

The tier 2 or mid-level players in the allergy care market are oriented toward solidifying their regional presence. Likewise, the emerging players or their tier 3 players are highly focused on specific product segments and boosting their volume sales.

Accessibility and affordability are two of the predominant factors retaining the unwavering demand for over-the-counter (OTC) medications for multiple purposes, with allergy care being no exception. As per a revelation by the Consumer Healthcare Products Association (CHPA), there has been a proactive shift toward OTC, with users scaled up to 75 percent in 2015, up from 66 percent in 2009. This provides enough credence to the fact that the demand for OTC medications is not foreseen to come down sooner.

Familiarity with the known is predominantly pushing the demand for branded OTC medications. The continued clamor for branded OTC medications for allergy care illustrates that though consumers are open to store-branded alternatives, they still remain highly inclined toward known brands in terms of reliability.

A Methodology of this Report is Available upon Request @ https://www.factmr.com/connectus/sample?flag=RM&rep_id=2382

Allergy Care Market to Witness a Paradigm Shift from Cure to Prevention

Allergy cases are rapidly increasing in prevalence, making the heavy dependency on pharmacotherapy for treatment seem unfeasible. As per a revelation by the Centers for Disease Control and Prevention (CDC), allergies stand as the 6th leading cause of chronic illness in the U.S. alone, with an annual cost of around $18 billion. Furthermore, a population of more than 50 million Americans suffers from different kind of allergies every year. According to the European Academy of Allergy and Clinical Immunology (EAACI), more than 150 million Europeans suffer from chronic allergic diseases as per the current scenario and half of the entire EU population is foreseen to be affected by 2025.

In line with the aforementioned alarming situation, allergy care market is witnessing several efforts and formulations focusing on prevention over cure. One of such compelling efforts was taken by Japan’s Astellas Pharma in formulation of a DNA vaccine, which was meant to protect the body from cedar pollen.

Genentech, Inc., a prominent biotechnology corporation, introduced omalizumab, which is an engineered antibody that binds to human IgE to treat a form of asthma. Developments as such are likely to carry promising potential ahead and might offer untapped opportunities for the market players to tap into.